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Figure S1. SMO inhibitors do not inhibit Gli-dependent luciferase activity in SUFU-KO-LIGHT cells. Cells were 
incubated with the indicated inhibitors for 24 h, and the resulting luciferase reporter activities were measured. Data are 
the average of three biological replicates ± s.e.m. 
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Figure S2. Bicyclic imidazoliums do not alter the subcellular localization of FLAG-GLI1. Western blot analyses of 
FLAG-GLI1-expressing NIH-3T3 cells treated with either 5 µM 10, 5 µM cyclopamine (Cyc), or DMSO vehicle for 4 h and 
then lysed and fractionated by centrifugation. Subcellular fractionation was confirmed using lamins and GAPDH as 
nuclear and cytosolic markers, respectively. A representative blot from three biological replicates is shown, and all 
samples were analyzed on the same blot.
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Figure S3. Activity profile of imidazolium 5 against the NCI60 cancer cell lines. Compound concentrations required for 
50% of maximal inhibition (GI50s) are shown. The H23 and H522 lines (asterisks) express high levels of GLI1.
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Figure S4. Bicyclic imidazoliums can disrupt mitochondrial membrane potential. NIH-3T3 cells were treated with the 
designated compounds for 24 h and then stained for 30 min with 500 nM tetramethylrhodamine (TMRM), which selectively 
labels mitochondria with a membrane potential. Scale bar: 100 µm. 
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Figure S5. Hh pathway inhibition does not alter mitochondrial respiration. Oxygen consumption rates (OCRs) 
of NIH-3T3 cells treated with varying doses of cyclopamine, as measured by the Seahorse Mito Stress assay. The 
SMO antagonist did not significantly inhibit OXPHOS as determined by one-way ANOVA against DMSO. Data are 
the average of three biological replicates ± s.e.m.
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General Methods. All reactions were performed in thick-walled pressure vessels under a positive 
pressure of nitrogen.  Stainless steel syringes or cannulae were used to transfer air- and moisture 
sensitive liquids.  Organic solutions were concentrated on Büchi R-200 rotary evaporators at ~20 
Torr (house vacuum) at 25–35 °C, then at ~1 Torr (vacuum pump) unless otherwise indicated.  
Column chromatography was performed using 200−300 mesh silica gel.  Commercial reagents 
and solvents were used as received unless otherwise noted. Compounds 1, 4, 11, and 12 were 
commercially available; the synthesis of 2, 3, 6, and 8 was contracted to Chao Che (Peking 
University); and the synthesis of 13 and 14  was contracted to Kemio Solutions (Bangalore, India). 
Compounds 5, 7, 9, and 10 were synthesized in-house. 
 
Instrumentation. Proton nuclear magnetic resonance (1H NMR) spectra were recorded with a 
Bruker 300, Bruker 500, or Varian 500 INOVA spectrometer. High resolution mass spectra 
(HRMS) were obtained on a quadrupole time-of-flight (QTOF) mass spectrometer.  Chemical 
shifts are reported in parts per million from internal tetramethylsilane on the δ scale and are 
referenced from the residual protium in the NMR solvent (CHCl3: δ 7.27 ppm, CD2HOD: δ3.31 
ppm, CD2HCN: δ1.94 ppm). 
 
General Procedure for the Synthesis of Bicyclic Imidazolium Compounds (D):  
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A mixture of aniline A (1.0 equiv) and azepine B (1.0 equiv) was heated to 85 ºC and stirred under 
a nitrogen atmosphere for 6 days. The resulting precipitate was collected by vacuum filtration and 
washed with 3×3 mL Et2O to yield a 7-amino-azepine intermediate E.  2-Bromoketone C (1.0 
equiv) was added to a pressure vessel charged with a suspension of the corresponding 7-amino-
azepine intermediate E (1.0 equiv) in THF (to 2.0 M) and the vessel was sealed and placed on an 
oil bath at 78 ºC.  The reaction mixture was stirred at 78 ºC for 16 h, then allowed to cool to room 
temperature and the solution was concentrated under reduced pressure.  The crude hydrate F 
was dissolved in acetic anhydride (to 1.5 M) in a pressure vessel, and the vessel was sealed and 
maintained on an oil bath at 120 ºC for 5 h. The vessel was then allowed to cool to room 
temperature and the reaction mixture was concentrated under reduced pressure.  The residue 
was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 1:20) to give bicyclic 
imidazolium compound D. 
 
Characterization data 
 
 
Bicyclic imidazolium compound S1 was prepared according to the General Procedure with A = 4-
ethoxyaniline, B = 7-methoxy-3,4,5,6-tetrahydro-2H-azepine, and C = N-(4-(2-
bromoacetyl)phenyl)-N-methylpropionamide, and used directly in the next step.  To the solution 
of (S1) (30 mg) in 5 mL of anhydrous THF was added NaBH4 (40 mg) and BF3OEt2 (0.2 mL) at 0 
ºC. The reaction mixture was stirred at 0 ºC for 1 h and at room temperature overnight. The reaction 
was then quenched with saturated aqueous NaHCO3 (5 mL), and extracted with CH2Cl2 (3×10 
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mL). The combined organic phase was concentrated under reduced pressure, and the residue 
was purified by flash column chromatography on silica gel (MeOH:CH2Cl2, 1:20) to yield desired 
product 2.  Yield = 87%; 1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 8.8 Hz, 2H), 7.30 (d, J = 8.8 
Hz, 2H), 7.04 (d, J = 8.8 Hz, 2H), 6.95 (s, 1H), 6.74 (d, J = 8.8 Hz, 2H), 4.40 (t, J = 4.4 Hz, 2H), 
4.12 (q, J = 6.8 Hz, 2H), 3.35 (t, J = 7.2 Hz, 2H), 3.26 (t, J = 5.2 Hz, 2H), 3.00 (s, 3H), 2.03 (d, J 
= 4.0 Hz, 2H), 1.84 (m, 2H), 1.74 (m, 2H), 1.59-1.68 (m, 2H), 1.47 (q, J = 6.8 Hz, 3H), 0.97 (t, J = 
7.2 Hz, 3H); HRMS (m/z) calc. for C26H34N3O (+) 404.2696, found 404.2694. 
 
 
Bicyclic imidazolium compound 3 was prepared according to the General Procedure with A = 4-
ethoxyaniline, B = 7-methoxy-3,4,5,6-tetrahydro-2H-azepine, and C = 2-bromo-1-(4-(pyrrolidin-1-
yl)phenyl)ethan-1-one.  Yield = 75%; 1H NMR (300 MHz, CDCl3) δ 7.50-7.55 (m, 2H), 7.26-7.30 
(m, 2H), 7.00-7.06 (m, 3H), 6.63 (d, J = 8.7 Hz, 1H), 6.44 (s, 2H), 4.43-4.46 (m, 2H), 4.13 (q, J = 
6.9 Hz, 2H), 3.31-3.35 (m, 4H), 1.76-2.08 (m, 12H), 1.47 (t, J = 6.9 Hz, 2H); HRMS (m/z) calc. for 
C26H32N3O (+) 402.2540, found 402.2535. 
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Bicyclic imidazolium compound 5 was prepared according to the General Procedure with A = 2-
methoxyaniline, B = 7-methoxy-3,4,5,6-tetrahydro-2H-azepine, and C = 1-([1,1'-biphenyl]-4-yl)-2-
bromoethan-1-one.  Yield = 89%.  1H NMR (500 MHz, CDCl3) 7.75 (d, J = 8.0 Hz, 2H), 7.45-7.63 
(m, 8H), 7.39 (tt, J = 7.4, 1.2 Hz, 1H), 7.11-7.16 (m, 2H), 7.11 (s, 1H), 4.22-4.40 (m, 2H), 3.88 (s, 
3H), 2.90-3.04 (m, 2H), 1.64-2.10 (m, 6H); HRMS (m/z) calc. for C27H27N2O (+) 395.2118, found 
395.2119. 
 
 
Bicyclic imidazolium compound 6 was prepared according to the General Procedure with A = 
[1,1'-biphenyl]-4-amine, B = 7-methoxy-3,4,5,6-tetrahydro-2H-azepine, and C = 2-bromo-1-(4-
ethoxyphenyl)ethan-1-one.  Yield = 55%; 1H NMR (500 MHz, CDCl3) δ 7.75-7.80 (m, 4H), 7.59-
7.61 (m, 2H), 7.46-7.49 (m, 4H), 7.40-7.43 (m, 1H), 7.10 (s, 1H), 6.99 (d, J = 9.0 Hz, 2H), 4.46 (t, 
J = 5.0 Hz, 2H), 4.07 (q, J = 7.0 Hz, 2H), 3.46 (t, J = 5.5 Hz, 2H), 2.05-2.08 (m, 2H), 1.89-1.91 
(m, 2H), 1.81-1.82 (m, 2H), 1.43 (t, J = 7.0 Hz, 3H); HRMS (m/z) calc. for C28H29N2O (+) 409.2274, 
found 409.2272. 
 
 
Bicyclic imidazolium compound 7 was prepared according to the General Procedure with A = 2-
methoxyaniline, B = 7-methoxy-3,4,5,6-tetrahydro-2H-azepine, and C = 2-bromo-1-(4-
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ethoxyphenyl)ethan-1-one.  Yield = 98%. 1H NMR (500 mHz, CDCl3) ∂ 7.55 (td, J = 7.9, 1.5 Hz), 
7.45 (dd, J = 8.2, 1.5 Hz, 1H), 7.34 (d, J = 8.6 Hz, 2H), 7.13 (d, J = 8.2 Hz, 1H), 7.10–7.14 (m, 
1H), 7.00 (d, J = 8.6 Hz, 2H), 7.01 (s, 1H), 4.24–4.29 (m, 2H), 4.06 (q, J = 7.0 Hz, 2H), 3.86 (s, 
3H), 2.87–3.02 (m, 2H), 1.62–2.09 (m, 6H), 1.41 (t, J = 7.0 Hz, 3H); HRMS (m/z) calc. for 
C23H27N2O2 (+) 363.2067, found 363.2067. 
 
 
Bicyclic imidazolium compound 8 was prepared according to the General Procedure with A = 4-
ethoxyaniline, B = 7-methoxy-3,4,5,6-tetrahydro-2H-azepine, and C = 2-bromo-1-(2-
methoxyphenyl)ethan-1-one.  Yield = 73%.  1H NMR (500 MHz, CDCl3) δ 7.61 (d, J = 9.0 Hz, 2H), 
7.49-7.53 (m, 2H), 7.08 (t, J = 6.5 Hz, 1H), 7.00-7.06 (m, 4H), 4.23 (t, J = 5.0 Hz, 2H), 4.07 (q, J 
= 7.0 Hz, 2H), 3.88 (s, 3H), 3.40 (t, J = 5.0 Hz, 2H), 2.06-2.09 (m, 2H), 1.88-1.90 (m, 2H), 1.79-
1.82 (m, 2H), 1.42 (t, J = 7.0 Hz, 3H); HRMS (m/z) calc. for C23H27N2O2 (+) 363.2067, found 
363.2068. 
 
Bicyclic imidazolium compound 9 was prepared according to the General Procedure with A = 2-
methoxyaniline, B = 2-methoxy-3,4-dihydroquinoline,1 and C = 1-([1,1'-biphenyl]-4-yl)-2-
bromoethan-1-one.  Yield = 40%.  1H NMR (500 MHz, CD3CN) δ 7.90 (m, 2H), 7.76 (m, 4H), 7.66 
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(m, 2H), 7.58 (m, 4H), 7.50 (m, 1H), 7.37-7.44 (m, 2H), 7.29 (m, 1H), 7.22 (m, 1H), 7.03 (d, J = 
8.5 Hz, 1H), 3.10-3.24 (m, 4H); HRMS (m/z) calc. for C30H25N2O (+) 429.1961, found 429.1958. 
 
 
  
Bicyclic imidazolium compound 10 was prepared according to the General Procedure with A = 2-
methoxyaniline, B = 2-methoxy-4,5-dihydro-3H-benzo[b]azepine,2 and C = 1-([1,1'-biphenyl]-4-
yl)-2-bromoethan-1-one.  Yield = 74%. 1H NMR (500 MHz, CDCl3, rotamers) 7.98-8.19 (m, 0.5H), 
7.23-7.68 (m, 15H), 7.20 (d, J = 8.6 Hz, 1H), 7.01-7.12 (br s, 1H), 6.49-6.69 (br s, 0.5 H), 3.97 (s, 
3H), 2.27-3.09 (m, 6H).  HRMS (m/z) calc. for C31H27N2O (+) 443.2118, found 443.2112. 
 
 
 
Indole 13. To a solution of 1H-indole (2.0 g) in DMSO (20 mL) was added 1-chloro-2-
methoxybenzene (2.92 g), K3PO4 (7.21 g), and copper oxide (0.424 g), followed by (1R,2R)-
N1,N2-dimethylcyclohexane-1,2-diamine (0.24 g) at room temperature.  The reaction mixture was 
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stirred at 90 ºC for 16 h, then cooled to room temperature, quenched with water, and extracted 
with ethyl acetate. The combined extracts were washed with water, brine, dried over anhydrous 
Na2SO4, filtered and concentrated.  The residue was purified by flash column chromatography on 
silica gel (EtOAc:hexanes, 3:7) to yield desired product S2. Yield = 34%. 
 
To a solution of 1-(2-methoxyphenyl)-1H-indole (S2, 1.0 g) in DMF (10 mL) was added N-
bromosuccinimide (1.19 g) at 0 ºC and stirred at room temperature for 6 h.  The reaction was 
quenched with water and extracted with CH2Cl2. The combined extracts were washed with water 
and brine, dried over anhydrous Na2SO4, filtered, and concentrated. The residue was purified by 
flash column chromatography on silica gel (EtOAc:hexanes, 1:9) to yield desired product S3. Yield 
= 64%. 
 
To a solution of 3-bromo-1-(2-methoxyphenyl)-1H-indole (S3, 0.20 g) and [1,1'-biphenyl]-4-
ylboronic acid (0.14 g) in 1:1 toluene:EtOH (4 mL) was added K2CO3 (0.22 g) and the mixture was 
purged with nitrogen for 5 minutes.  Pd(PPh3)4 was added and the mixture was stirred at 90 °C 
for 4 h.  The reaction was quenched with water and extracted with EtOAc. The combined extracts 
were washed with water, brine, dried over anhydrous Na2SO4, filtered and concentrated. The 
residue was purified by flash column chromatography on silica gel (EtOAc:hexanes, 3:7) to yield 
desired product 13. Yield = 20%. 1H NMR (400 MHz, CDCl3) δ8.03 (dd, J = 6.4, 2.8 Hz, 1H), 7.81 
(d, J = 8.2 Hz, 3H), 7.68 (dd, J = 11.8, 7.9 Hz, 3H), 7.53 – 7.41 (m, 3H), 7.44 – 7.31 (m, 2H), 7.25 
(ddd, J = 14.6, 6.1, 3.4 Hz, 2H), 7.16 – 7.06 (m, 1H), 3.81 (s, 2H), 1.35 (d, J = 15.3 Hz, 1H), 1.29 
(s, 1H), 1.27 (d, J = 11.8 Hz, 2H), 0.91 – 0.82 (m, 1H). HRMS (m/z) calc. for C27H22NO (+) 
376.1618, found 376.1616. 
13
  
Pyrazole 14. To a solution of 4-(pyridin-3-yl)benzoyl chloride (0.80 g) in CH2Cl2 (8.0 mL), (2-
methoxyphenyl)hydrazine (0.50 g) was added, then Et3N (0.72 g) was added dropwise.  The 
reaction mixture was stirred at room temperature for 1.5 h, then an additional (2-
methoxyphenyl)hydrazine (0.50 g) and Et3N (0.72 g) were added and the mixture was stirred at 
room temperature for 16 h.  The reaction was quenched with aqueous NaHCO3 and extracted 
with CH2Cl2.  The organic layer was concentrated to yield S4, which was used in the next step 
without further purification. 
 
To a solution of S4 (0.50 g) and triphenylphosphine (0.48 g) in acetonitrile (2 mL) was added CCl4 
(2 mL), and the reaction mixture was stirred at room temperature for 1 h and then at 50 °C for 16 
h.  The reaction was quenched with water and extracted with EtOAc. The combined extracts were 
washed with water, brine, dried over anhydrous Na2SO4, filtered, and concentrated. The residue 
was purified by flash column chromatography on silica gel (EtOAc:hexanes, 3:7) to yield desired 
product S5. Yield = 68%. 
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To a solution of S5 (0.35 g) in toluene (4 mL) was added cycloheptene (0.49 g), Et3N (0.40 mL), 
and the mixture was stirred at 110 °C for 3 h, then at room temperature for 16 h.  The reaction 
was quenched with water and extracted with EtOAc, the combined extracts were washed with 
water, brine, dried over anhydrous Na2SO4, filtered, and concentrated. The residue was purified 
by flash column chromatography on silica gel (EtOAc:hexanes, 3:7) to yield desired product S6. 
Yield = 38%. 
 
To a stirred mixture of S6 (150 mg) in toluene (2 mL), was added p-chloranil (101 mg) and the 
mixture was heated to 110 °C for 3 h.  The reaction was quenched with water and extracted with 
EtOAc.  The combined extracts were washed with water, brine, dried over anhydrous Na2SO4, 
filtered, and concentrated.  The residue was purified by flash column chromatography on silica 
gel (EtOAc:hexanes, 1:4), followed by preparative thin-layer chromatography (EtOAc:hexanes, 
3:20) to give the desired product 14.  Yield = 63%.  1H NMR (400 MHz, CDCl3) δ7.73 – 7.66 (m, 
3H), 7.63 (dd, J = 8.1, 1.5 Hz, 6H), 7.47 – 7.42 (m, 4H), 7.42 – 7.36 (m, 2H), 7.36 – 7.28 (m, 2H), 
7.09 – 6.98 (m, 3H), 3.81 (s, 4H), 2.83 (t, J = 5.6 Hz, 3H), 2.61 (s, 1H), 2.53 (s, 1H), 1.91 – 1.82 
(m, 3H), 1.55 (s, 2H). HRMS (m/z) calc. for C27H28N2O (+) 396.2117, found 39.2118. 
1 T. Tsuritani, Y. Yamamoto, M. Kawasaki, T. Mase, Org. Lett. 2009, 11, 1043–1045. 
2 D. R. Cheshire, IDrugs, 2001, 4, 795–803. 
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Materials and Methods 
 
High-throughput screen for small-molecule antagonists of Gli function 
The high-throughput chemical screen for inhibitor of Gli function was contracted to the Conrad Prebys 
Center for Chemical Genomics at the Sanford Burnham Prebys Medical Discovery Institute. The screen 
conditions were equivalent to those described in PubChem AID 588413. In brief, 5 x 103 SUFU-KO-LIGHT 
cells were seeded into white 1536-well plates. 16 to 18 hours after seeding, the cells were treated with 
individual compounds at the final concentration of 5 µM and cultured for another 16 to 18 hours. The cells 
were then treated with Bright-Glo luciferase substrate (3 µL/well; Promega) for 10 minutes at room 
temperature before luminescence was read on a Viewlux microplate imager. Hits with at least 50% 
luciferase inhibition were expanded for a dose-response assay, and those with IC50s lower than 20 µM 
were subsequently counter-screened in cytotoxicity, luciferase, and WNT assays.  
 
Cell lines and cell culture 
SUFU-KO-LIGHT: DMEM containing 10% fetal bovine serum (FBS), 1% sodium pyruvate, 1% 
penicillin/streptomycin (pen/strep), 150 µg/mL zeocin, and 400 µg/mL geneticin 
 
NIH-3T3 and NIH-3T3 FLAG-GLI1: DMEM containing 10% calf serum (CS), 1% sodium pyruvate, and 1% 
pen/strep  
 
NIH-3T3-r0: DMEM containing 10% CS, 1% sodium pyruvate, 1% pen/strep , 100 ng/mL ethidium bromide, 
and 50 µg/mL uridine (minimum of 6 days to ensure loss of functioning electron transport chain) 
 
C3H10T1/2: DMEM containing 10% FBS, 1% sodium pyruvate, and 1% pen/strep 
 
Murine embryonic fibroblasts (WT and Gli1–/–[1] MEFs): DMEM containing 10% CS, 1% sodium pyruvate, 
1% pen/strep, and 1% non-essential amino acids 
 
Wnt3a-expressing L: DMEM containing 10% FBS, 1% pen/strep 
 
WNT-LIGHT: DMEM containing 10% FBS, 1% pen/strep , and 1.5 mM geneticin 
 
SHH-producing HEK 293: DMEM containing 10% FBS, 1% sodium pyruvate, 1% pen/strep, 1.5 mM 
geneticin   
 
All cell lines were grown at 37 °C with 5% CO2. Serum starvation was performed in media lacking phenol 
red and containing either 0.5% FBS or CS. 
 
Generation of stable cell lines 
SUFU-KO-LIGHT: Embryonic fibroblasts derived from Sufu knockout mice (Sufu–/– MEFs[2]) were co-
transfected with a zeocin resistance vector and a firefly luciferase reporter driven by eight tandem Gli-
binding sites and a basal d-crystallin promoter (8xGliBS:luciferase). After selection, the cell line was co-
transfected with SV40 promoter-driven Renilla luciferase reporter (pRLSV40; Promega) and a puromycin 
resistance vector. Dilution cloning in puromycin-containing medium (1 µg/mL) then yielded the SUFU-KO-
LIGHT line. 
 
WNT-LIGHT: L-cells (ATCC) were co-transfected with the SuperTopFlash reporter[3], which contains seven 
tandem TCF/LCF binding sites and the firefly luciferase coding region, pRLSV40, and pcDNA3 (Invitrogen; 
for geneticin resistance). Ring cloning in geneticin-containing medium (1 mg/mL) then yielded the WNT-
LIGHT line.   
 
NIH-3T3 FLAG-GLI1: NIH-3T3 cells were retrovirally transduced with pBMN-TAG2-IRES-mCherry 
containing the mouse Gli1 coding sequence at a multiplicity of infection (MOI) of 0.3. Two days after 
infection, mCherry-positive cells were isolated by fluorescence-activated cell sorting and expanded. 
 
  
26
SHH-conditioned medium 
The SHH N-terminal domain was stably expressed in HEK-293T-EcR cells. Cells were grown to 80% 
confluency, and medium was changed to DMEM containing 2% FBS. SHH-conditioned medium was 
collected after two days and sterilized using a 0.22-µm filter. The SHH titer was determined by adding serial 
dilutions of conditioned medium to SHH-LIGHT2 cells, an NIH-3T3 fibroblast-derived line that is stably 
transfected with 8xGliBS:luciferase and pRLSV40 reporters. SHH-conditioned medium was used at a 
concentration two-fold greater than minimum dilution required for maximum SHH pathway activation 
(typically 1:10).  
 
WNT3A-conditioned medium 
WNT3A ligand was stably expressed in L cells. After the cells reached 100% confluency, the medium was 
collected, centrifuged at 500 g for 10 minutes, passed through a 0.22-µm filter, and stored for up to two 
weeks at 4 °C.  
 
Western blot 
Samples were lysed in 1X SDS-PAGE loading buffer, boiled, sonicated, and resolved on a 3-8% Tris-
acetate Criterion gel (Bio-Rad) in XT Tricine buffer. Proteins were then transferred to a PVDF membrane 
using a Bio-Rad Transblot Turbo system. Membranes were blocked in 5% non-fat dry milk in Tris-buffered 
saline containing 0.1% Tween-20 (TBST) or 1:1 phosphate-buffered saline (PBS)/Seablock (for GLI1) for 
1 hour at room temperature. The blots were then incubated with primary antibody overnight at 4 °C and 
with HRP-conjugated secondary antibody for 1 hour at room temperature. Chemiluminescent detection of 
the HRP-conjugated secondary antibodies was conducted with Supersignal West Femto Maximum 
Sensitivity Substrate (Thermo Fisher Scientific) and a ChemiDoc MP imaging system (Bio-Rad). Image 
quantification was performed using ImageJ. 
 
qPCR 
NIH-3T3 cells and Gli1–/– MEFs were seeded into 6-well plates at a density of 6.5 x 105 cells/well or 24-well 
plates at a density of 1.2 x 105 cells/well.  After 24 hours, the cells were cultured in serum starvation medium 
containing various concentrations of compound (with or without SHH) for 24 hours, unless indicated 
otherwise. After 24 hours, RNA was extracted using the Monarch Total RNA Miniprep kit, and the 
SuperScript III First-Strand Synthesis kit was used to generate cDNA. Samples were incubated with 
TaqMan FAM probes, and qPCR was performed on a Roche LightCycler 480. Cycle numbers were 
normalized to the housekeeping gene B2M. 
 
Immunofluorescence microscopy 
NIH-3T3 cells were seeded onto poly-D-Lysine-coated coverslips in 24-well plates at a density of 1.2 x 105 
cells/well. After 24 hours, the cells were cultured in serum starvation medium containing various 
concentrations of compound (with or without SHH) for the indicated times.  
 
To determine the effects of compounds on ciliary GLI2 levels, NIH-3T3 cells were pre-treated with SHH for 
24 hours and then cultured with the indicated compounds for 6 hours. The cells were subsquently fixed in 
4% paraformaldehyde for 10 minutes at room temperature and permeabilized with ice-cold methanol for 
5 minutes at -20 °C. Coverslips were stained with primary antibodies (GLI2, ARL13B, and g-tubulin), Alexa 
Fluor dye-labeled secondary antibodies, and DAPI and then imaged with a Zeiss Axio Imager M1 
eplfluorescence microscope controlled by SlideBook software (Intelligent Imaging Innovations). GLI2 ciliary 
tip intensity was determined as previously described[4]. Briefly, a ciliary mask was generated using ARL13B 
immunofluorescence, and g-tubulin staining was used to identify the cilium base. Ciliary GLI2 levels were 
determined by integrating GLI2 immunofluorescence signals in the last five pixels of the distal tip.  
 
To evaluate the subcellular localization of FLAG-GLI1, NIH-3T3 cells were treated with the indicated 
compounds for 4 hours, fixed with 4% paraformaldehyde for 10 minutes at room temperature, and 
permeabilized with 0.3% Triton X-100. Coverslips were stained with anti-FLAG primary antibody overnight 
at 4 °C , and the following day with Alex Fluor 488 IgG secondary antibody for 1 hour at room temperature 
in the dark, and mounted with DAPI. The immunostained cells were then imaged on a Zeiss LSM 800 
confocal microscope equipped with ZEN Blue software. The ratio of cytoplasmic:nuclear FLAG-GLI1 was 
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determined by creating a mask based on the DAPI signal and comparing the average pixel intensities within 
the mask (nuclear) and at least 10 pixels outside of the mask (cytoplasmic).  
 
To assess mitochondrial morphology, NIH-3T3 cells co-treated with SHH and the indicated compounds for 
24 hours and then stained with 500 nM MitoTracker Deep Red FM for 30 minutes at 37 °C. Cells were fixed 
with 4% paraformaldehyde and permeabilized in ice-cold methanol for 15 minutes at -20 °C. Coverslips 
were imaged on a Zeiss LSM 800 with ZEN Blue software. Mitochondrial morphology was manually scored 
for normal (elongated and branched) and disrupted (perinuclear and rounded) phenotypes.  
 
SUFU-KO-LIGHT assay 
SUFU-KO-LIGHT cells were seeded into 96-well plates at a density of 3.5 x 104 cells/well. After 24 hours, 
the cells were cultured in serum starvation medium containing the indicated compounds for another 
24 hours.  20 µL/well CellTiter AQueous One (Promega) was then added to the cells and incubated for 
30 minutes at 37 °C. Cell viability was measured as absorbance at 490 nm of the culture media on a 
Molecular Devices Spectramax M2e. Cells were then washed with PBS and incubated with 100 µL/well 
Bright-Glo reagent for 5 minutes at room temperature. Gli-dependent firefly luciferase activity was 
measured on a Veritas luminometer and normalized to the CellTiter signal. Dose-response curves were 
generated using Prism software (GraphPad).  
 
WNT-LIGHT assay 
WNT-LIGHT cells were seeded into 96-well plates at a density of 1 x 104 cells/well. After 24 hours, the cells 
were cultured in a 1:1 ratio of WNT3A-conditioned medium and serum starvation medium for another 
24 hours. The cells were then lysed using a Dual Luciferase kit (Promega), and TCF/LEF-dependent firefly 
luciferase activity was measured on a Veritas luminometer and normalized to Renilla luciferase levels. 
 
CMV-luciferase assay 
NIH-3T3 cells were seeded into a 24-well plate at density of 3.5 x 104 cells/well. After 24 hours, the cells 
were approximately 50% confluent and co-transfected with pRLSV40 (5 ng/well), a CMV-driven firefly 
luciferase expression vector (15 ng/well), and TransIT-LT1 reagent (Mirus Bio). The medium was changed 
the following day, and the cells were cultured for an additional 24 hours until they reached 100% confluency.  
The cells were then cultured in serum starvation medium containing the indicated compounds for another 
24 hours. Cells were then lysed using the Dual Luciferase kit, and firefly and Renilla luciferase activities 
were measured on a Veritas luminometer.  
 
Alkaline phosphatase assay 
C3H10T1/2 cells were seeded into a 96-well plate at a density of 2.5 x 104 cells/well. After 24 hours, the 
cells were cultured for another 48 hours in a serum starvation medium containing 10% SHH-conditioned 
medium and the indicated compounds. The cells were then treated with 50 µL lysis buffer (100 mM Tris-
HCl, pH 9.5, 250 mM NaCl, 25 mM MgCl2, and 1% Triton X-100) and rocked for 45 minutes at room 
temperature. 10 µL of lysate was transferred to a white-wall 96-well plate and incubated with 50 µL CDP-
Star reagent (NEB) for 15 minutes at room temperature in the dark. Luminescence was measured on a 
Veritas luminometer. 
 
Seahorse XF Mito Stress assay 
NIH-3T3 or NIH-3T3-r0 cells were seeded into an XF96 plate at a density of  9 x 103 cells/well. After 24 
hours, the cells were incubated for 1 hour at 37 °C in a non-CO2 incubator. Cells were then loaded into a 
96-well Seahorse XF analyzer (Agilent) and sequentially injected with the indicated compounds, 1 µM 
oligomycin A, 1 µM FCCP, or 0.5 µM rotenone/antimycin according to the Agilent Mito Stress protocol. The 
oxygen consumption rate (OCR, pmol/min) was measured every 5 minutes for a 15-minute period, and 
oxidative phosphorylation capacity was determined by background-subtracting the average oligomycin 
value from of each reading, and normalizing the data to the DMSO control.  
 
NCI-60 cancer cell line proliferation and COMPARE analysis 
Inhibitor 5 was tested by the NIH against its panel of approximately 60 human cancer cell lines at 5 different 
doses (100 µM, 10 µM, 1 µM, 0.1 µM, and 0.01 µM) over the course of 7 days according the NCI-60 
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screening methodology[5]. COMPARE analysis was then performed by cross-correlating the NCI-60 
inhibition profile for inhibitor 5 against those of over 80,000 synthetic compounds.  
 
Nuclear and cytoplasmic fractionation 
FLAG-GLI1-expressing NIH-3T3 cells were seeded into 6-well plates at a density of 6 x 105 cells/well. After 
24 hours, cells were treated with indicated compounds for 24 hours. The cells were then lysed and 
separated into nuclear and cytoplasmic fractions using an NE-PER kit (Thermo Fisher Scientific), according 
to the manufacturer’s protocols. 
 
Mitochondrial membrane potential 
NIH-3T3 cells were seeded into 24-well plates at a density of 1.2 x 105 cells/well.  After 24 hours, the cells 
were cultured for another 24 hours in serum starvation medium containing 10% SHH-conditioned medium 
and the indicated compounds. The medium was then supplemented with TMRM and Mitotracker Deep Red 
(500 nM final concentrations for each) and DAPI, and the cells were incubated in this medium for 30 minutes 
at 37 °C. Cells were then washed, maintained in serum starvation medium without phenol red, and imaged 
on a BZ-X700 Keyence microscope equipped with BZ-X analyzer software.   
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Reagent Supplier and Catalog Number 
Primary antibodies 
GLI1 Cell Signaling Technologies L42B10 
GLI2 R&D systems AF3635 
GLI3 R&D Systems AF3690 
FLAG Sigam-Aldrich F1804 
Karyopherin subunit beta 1 Santa Cruz sc-137016 
Arl13b UC Davis/NIH NeuroMab Clone N295B/66 
Gamma-tubulin Sigma Aldrich T6557 
Secondary antibodies 
Affinipure goat anti-mouse IgG (H+L) Jackson Immunoresearch #115-005-166 
Bovine anti-goat IgG (H+L) Jackson Immunoresearch #805-035-180 
Sheep anti-mouse IgG GE Sciences NA931 
TaqMan probes 
Gli1 Mm00494645 
Ptch1 Mm00436026 
B2M Mm00437762 
Kits 
Seahorse XF Mito Stress Test Agilent Technologies 103015 
Seahorse XFe FluxPak Agilent Technologies 102601 
NE-PER nuclear and cytoplasmic kit Thermo Fisher 78833 
Dual-Luciferase reporter system Promega E1910 
Bright-Glo luciferase system Promega E2610 
Compounds/Other 
Cyclopamine Sigma Aldrich C4116 
Oligomycin A Sigma Aldrich 75351 
Tetramethylrhodamine Thermo Fisher T668 
CDP-Star substrate (0.25 mM) Thermo Fisher T2146 
L Wnt-3A cells ATCC 2647 
DAPI ProLong Gold Antifade Thermo Fisher P36931 
Mitotracker Deep Red M22426 
Bicyclic imidazolium 
analogs 
Bicyclic imidazolium 1 MolPort, MolPort-007-793-026 
Bicyclic imidazolium 4 Princeton BioMolecular Research, OSSK_001861 
Bicyclic imidazolium 11 Aurora Fine Chemicals LLC, K00.358.921 
Bicyclic imidazolium 12 Aurora Fine Chemicals LLC, A35.152.540 
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